Gwyneth Paltrow is an Oscar winning actor but today is perhaps better known for her lifestyle and wellness brand Goop. And she is the latest in a string of celebrities to invest in CBD products.
According to reports from CNBC, Paltrow has invested an unspecified amount into cannabis drinks company Cann. Headline grabbing investments in CBD products shows just how mainstream medicinal cannabis is becoming.
Celebrity endorsements always push a new market to the next level as consumers become more aware of their stance. And it’s the same with legal medicinal cannabis around the world. …
Why investment in medicinal cannabis is becoming more mainstream
As legal cannabis moves further into the mainstream, could this be a good time to invest in the burgeoning market? Let’s look at some of the signs of growth in this market and why investment in medicinal cannabis is becoming more and more viable for individual investment.
Why is individual investment in medicinal cannabis becoming more popular?
According to the Centre for Medicinal Cannabis (CMC) in its 2019 report, around six million people in the UK have tried CBD. Short for cannabidiol, CBD is a chemical compound derived from cannabis. It is, of course, the non-psychoactive ingredient in cannabis unlike delta-9 tetrahydrocannabinol (THC). In other words, CBD does not get…
Could cannabis be part of an effective treatment for COVID-19?
Six months into the pandemic and more than 27 million people have been infected with COVID-19 worldwide. Almost 900,000 have died and active cases right now average at seven million.
Scientists, governments and biotechs are scrambling to find a vaccine or treatment for a disease that is changing our world. And there are some research groups looking into the potential of using cannabis in a treatment for COVID-19.
Could cannabis be a treatment for COVID-19?
Before we look at whether cannabis could be a cure for COVID-19, I want to quickly sum up where the race for a cure stands. Early potential treatments for new diseases usually…
Carl Esprey
Carl Esprey is CEO of Botanical Holdings, an investment company focusing on the legalised medical cannabis space.
